Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week open-label extension study of oral ziprasidone in adolescents with schizophrenia
2005-005502-23Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ziprasidone in schizophrenia, sponsored by Pfizer. Primary endpoint: Long-term safety. Started Dec 2005; status: terminated.
02
Drugs
ziprasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2005-005502-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005502-23.